We’ve been following various new developments in clear cell renal cell carcinoma (ccRCC) for a while now with the emergence of the HIF2α inhibitors belzutifan (Merck via Peloton), and more recently, casdatifan (Arcus Bio).

Musee D’orsay Paris, France

At the recent International Kidney Cancer Symposium in Paris, Kura presented updated phase 1 data for their next generation farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) combined with cabozantinib in ccRCC.

The response rate turned heads – 44% in patients who had already been treated with cabozantinib. It needs to be considered as an emerging signal since these data are still very early, the patient numbers small, and there are some important questions the poster cannot yet answer.

In this review, we take a look through the window at what the phase 1 data actually tells us and where the RCC field is likely heading in the near to medium term given other related and recent developments…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers